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Abstract
Objective Bariatric procedures that exclude the proximal
small intestine lead to significant weight loss which is proba-
bly mediated by changes in hormones that alter appetite, such
as peptide YY (PYY), ghrelin, cholecystokinin (CCK), and
leptin. Here, the effect of the non-surgical duodenal-jejunal
bypass liner (DJBL) on concentrations of hormones implicat-
ed in appetite control was investigated.
Subjects A two-center prospective study was conducted be-
tween January and December 2010. Seventeen obese subjects
with type 2 diabetes were treated with the DJBL for 24 weeks.
Fasting concentrations of leptin and meal responses of plasma
PYY, CCK, and ghrelin were determined prior to and after
implantation of the DJBL.
Results At baseline, subjects had an average body weight of
116.0±5.8 kg. One week after implantation, subjects had lost
4.3±0.6 kg (p<0.01), which progressed to 12.7±1.3 kg at
week 24 (p<0.01). Postprandial concentrations of PYY and
ghrelin increased (baseline vs. week 1 vs. week 24 PYY: 2.6±
0.2 vs. 4.1±0.4 vs. 4.1±0.7 nmol/L/min and ghrelin: 7.8±1.8
vs. 11.0±1.8 vs. 10.6±1.8 ng/mL/min, all p<0.05). In paral-
lel, the CCK response decreased (baseline vs. week 1 vs. week
24: 434±51 vs. 229±52 vs. 256±51pmol/L/min, p<0.01).
Fasting leptin concentrations also decreased (baseline vs.
week 24: 98±17 vs. 53±10 ng/mL, p<0.01).
Conclusions DJBL treatment induces weight loss paralleled
by changes in concentrations of hormones involved in appetite
control.
Keywords Satiety . Bariatric surgery . Obesity . Gut
hormones
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Introduction
Maintaining weight loss following treatment of obesity with
lifestyle interventions or drugs remains a challenge [1, 2].
Bariatric surgery is considered to be an effective strategy to
achieve long term reduction of body weight [3] because it
increases satiety and decreases caloric intake [4, 5]. These
changes seem to be mediated by changes in appetite regulat-
ing hormones, such as peptide YY (PYY), glucagon-like pep-
tide-1 (GLP-1), cholecystokinin (CCK), ghrelin, and leptin
[6–8].
Whereas CCK, PYY, GLP-1, and ghrelin are gut hormones
predominantly involved in short term signaling in relation to
intraluminal food content, the adipokine leptin, is a long term
regulator of energy balance [9]. In obese individuals, plasma
CCK levels have been reported to be low [10], and postpran-
dial PYY response is attenuated [11], while ghrelin levels are
also low [12, 13]. Furthermore, obesity is characterized by
high levels of leptin which do not temper appetite because
of leptin resistance [9, 14].
Bariatric procedures have been suggested to alter hormonal
responses thereby affecting satiety. In particular, the Roux-en-Y
gastric bypass (RYGB) leads to increased satiety and postpran-
dial PYY and GLP-1 levels [15–17]. Little is known about
changes in the CCK response after bariatric surgery [18, 19],
while the effects on ghrelin levels are controversial [18, 20].
Leptin levels have been reported to decrease after bariatric pro-
cedures, mirroring weight loss [21].
Recently, a non-surgical bariatric technique, the duodenal-
jejunal bypass liner (DJBL, GI Dynamics, Lexington, MA),
was developed to treat obesity. The DJBL is a 60-cm long
impermeable liner which is delivered and retrieved endoscop-
ically. Once in place, it mimics the intestinal bypass compo-
nent of the RYGB. Previously, DJBL treatment has been
shown to result in weight loss and improvement of type 2
diabetes [22–24].
We aimed to investigate the effect of duodenal-jejunal
exclusion by DJBL on fasting and postprandial plasma
concentrations of hormones involved in appetite control.
CCK, ghrelin, and PYY responses to a standard meal and
fasting leptin levels were studied in subjects with obesity
and type 2 diabetes prior to and after DJBL implantation.
Subjects and Methods
Subjects
Seventeen subjects with obesity and type 2 diabetes were in-
cluded in the Maastricht University Medical Center,
Maastricht, and the AtriumMedical Center Parkstad, Heerlen,
the Netherlands. Inclusion criteria were as follows: age be-
tween 18 and 65 years; body mass index (BMI) between 30
and 50 kg/m2; duration of type 2 diabetes less than 10 years;
and a HbA1c between 7.5 and 10.0 %. Main exclusion criteria
were as follows: weight loss of more than 4.5 kg within
12 weeks prior to screening; use of weight loss medication;
use of anticoagulation medication, NSAIDs, or corticoste-
roids; iron deficiency or anemia; gastrointestinal abnormali-
ties; gastroesophageal reflux disease; symptomatic gallstones
or kidney stones; known infection including Helicobacter
pylori; history of coagulopathy or upper gastrointestinal
bleeding conditions, connective tissue disorder, and severe
kidney or liver failure. All procedures performed were in ac-
cordance with the ethical standards of the institutional and/or
national research committee and with the 1964 Helsinki dec-
laration and its later amendments or comparable ethical stan-
dards. Informed consent was obtained from all individual par-
ticipants included in the study.
The DJBL Procedure
The DJBL was delivered and retrieved endoscopically as pre-
viously described [23]. In brief, a gastroduodenal endoscopy
was performed under general anesthesia. A guide wire was
placed into the duodenum over which the encapsulated DJBL
was directed through the pylorus into the duodenal bulb. The
DJBL was advanced into the small intestine, followed by de-
ployment of the anchor in the duodenal bulb. Correct posi-
tioning and patency of the DJBL were verified under
fluoroscopy.
After 24 weeks, removal of the DJBL was performed en-
doscopically under general anesthesia by the use of a custom
retrieval system containing a grasper and a retrieval hood. By
grasping the retrieval suture on the proximal face of the an-
chor, the anchor collapsed and was pulled into the retrieval
hood at the distal end of the endoscope. After verification of
the collapsed anchor by fluoroscopy, the device was removed.
Study Design
Subjects were studied on three occasions: (1) within 1 month
prior to implantation, (2) 1 week after implantation, and 3)
24 weeks after implantation, just prior to removal. After im-
plantation of the DJBL, subjects were provided a standard of
care bariatric nutritional counseling program, which suggested
a regular diet with a maximum of 1200 kcal for women and
1500 kcal for men. For safety reasons, liquid nutrition was
advised for the first week after DJBL placement. At every
visit, body weight was determined and subjects were asked
if their satiety and caloric intake had increased, decreased, or
was unchanged when compared to baseline. Daily caloric in-
take was evaluated by a dietitian and if necessary, dietary
adaptations were made. Additionally, a standardized meal tol-
erance test was performed: venous blood samples were drawn
after an overnight fast; subsequently a standard liquid meal
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was consumed (Ensure Plus, Abbott Laboratories, IL;
333 mL, 500 kcal, 20.8 g protein, 67.3 g carbohydrates, and
16.4 g fat), followed by collection of blood samples after 10,
30, 60, 90, and 120 min (BD Vacutainer EDTA tube/EDTA
aprotinin tube, BD diagnostics, Erembodegem-Aalst,
Belgium). Samples were immediately cooled, centrifuged,
and stored at −80 °C until analysis.
Plasma Hormone Assays
Plasma levels of total PYY and leptin were measured respec-
tively by radioimmunoassay and sandwich ELISA, as previ-
ously described [25, 26]. Plasma CCKwas determined using a
commercially available CCK-radioimmunoassay according to
the manufacturer’s protocol (Euro-diagnostica, Malmö,
Sweden). Plasma active ghrelin concentrations were assessed
with the human diabetes bio-plex pro assay (Bio-Rad
Laboratories BV, Veenendaal, the Netherlands) using
Luminex xMAP technology. The assay was performed with
a Luminex 100 IS 2.3 system using Bio-Plex Manager 4.1.1.
software as described by the manufacturer’s instructions.
Statistical Analyses
GraphPad Prism 5.0 and Statistical Package for Social Sci-
ences 17.0 were used. The area under the curve (AUC) was
calculated using GraphPad Prism. Longitudinal changes were
tested with linear mixed models in SPSS. The correct covari-
ance structure for the repeatedmeasures was chosen according
to Akaike Information Criterion and Bayesian Information
Criterion values. Nonparametric bivariate correlations were
tested with Spearman’s correlation coefficient. A p value of
<0.05 was considered statistically significant. Data are pre-
sented as statistical model estimated mean and standard error
of the mean (SEM).
Results
Exclusion of the Proximal Small Intestine byDJBLAffects
Body Weight
At baseline, subjects (14 males, 3 females) were 51±2 years
old and weighed 116.0±5.8 kg with a BMI of 37.0±1.3 kg/
m2. One week after placement of the DJBL, body weight had
decreased by 4.3±0.6 kg, corresponding to an excess weight
loss of 10.2±1.7 % and a BMI reduction of 1.4±0.2 kg/m2
(p<0.01). After 24 weeks, at the time of device removal, mean
body weight had further decreased resulting in a total weight
loss of 12.7±1.3 kg, with an excess weight loss of 29.8±3.5%
and a BMI reduction of 4.1±0.4 kg/m2 (p<0.01). All subjects
reported a reduction in caloric intake during the study, and
88 % of the subjects (15/17) reported increased satiety.
Rapid increase of PYYAfter DJBL Implantation
As shown in Fig. 1a, prior to DJBL placement, PYY only
increased marginally in response to a meal. Within 1 week
after placement, the AUC of the PYY response increased sig-
nificantly (baseline: 2.6±0.2 vs. week 1: 4.1±0.4 nmol/L/min,
p<0.01, Fig. 1b). This increase sustained during the remainder
of the study period (baseline: 2.6±0.2 vs. week 24: 4.1±
0.7 nmol/L/min, p<0.05). Furthermore, fasting PYY levels
increased, reaching significance at week 24 (baseline: 17.0±
1.5 vs. week 24: 23.1±2.7 pmol/L, p<0.05).
Decreased Postprandial CCK Response After DJBL
Implantation
Before DJBL placement, CCK levels increased rapidly fol-
lowing meal ingestion (Fig. 1c). After DJBL placement, this
postprandial peak was still observed, but the maximal CCK
concentration decreased strongly from 7.8±1.2 pmol/L at
baseline to 3.3±1.1 and 3.8±1.0 pmol/L at week 1 and week
24, respectively. This resulted in a decreased AUC for CCK
(baseline: 434±51 vs. week 1: 229±52 and baseline: 434±51
vs. week 24: 256±51 pmol/L/min, both p<0.01, Fig. 1d).
DJBLTreatment Results in Changes in Fasting
and Postprandial Ghrelin Levels
A postprandial decline in plasma levels of ghrelin, suggesting
inhibition of hunger after meal consumption, was present at
baseline (Fig. 1e). After DJBL placement, fasting ghrelin
levels increased (baseline: 38.8±19.9 vs. week 1: 120.7±
20.2 pg/mL and baseline: 38.8±19.9 vs. week 24: 137.1±
19.9 pg/mL, p<0.05 and p<0.01 respectively). Interestingly,
the difference between fasting and nadir ghrelin levels also
increased after placement of the DJBL, resulting in compara-
ble nadir of plasma ghrelin levels at 90 min postprandially.
Though, the AUC for ghrelin increased after DJBL placement
(baseline: 7.9±1.8 vs. week 1: 11.0±1.8 ng/mL/min and base-
line: 7.9±1.8 vs. week 24: 10.6±1.8 ng/mL/min, p<0.05 and
p<0.01, respectively, Fig. 1f).
Leptin Levels Decrease in Relation to Weight Loss
After DJBL Implantation
At baseline, fasting plasma leptin levels correlated with BMI
(rs=0.65, p<0.01). After DJBL placement, leptin levels de-
creased, reaching statistical significance at week 24 (baseline:
98±17 vs. week 1: 80±15 ng/mL and baseline: 98±17 vs.
week 24: 53±10 ng/mL, p=0.11 and p<0.01, respectively,
Fig. 1g). In addition, plasma leptin levels and BMI remained
correlated at both week 1 and week 24 (week 1: rs=0.87,
p<0.01 and week 24: rs=0.58, p=0.02, respectively).
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Discussion
Bariatric surgery leads to extensive weight loss. Additionally,
several changes in human physiology occur; alterations in
satiety, taste, and food preference have been described
[27, 28]. These changes are considered essential for losing
weight. Bypassing the duodenum and jejunum by DJBL
treatment has previously been shown to induce weight loss
[22, 23]. In the current study, the effect of the DJBL on satiety
hormones CCK, PYY, ghrelin, and leptin was investigated.
Whereas CCK is secreted in the proximal small intestine in
response to intraluminal nutrients and signals satiety via vagal
afferents [29], PYY is secreted by L-cells predominantly in the
distal gastrointestinal tract and reduces food intake by





















































































































Baseline Week 1 Week 24Fig. 1 Effects of DJBL treatment
on fasting and postprandial PYY,
CCK, ghrelin, and fasting leptin.
a Plasma PYY concentrations
during the meal tolerance test at
baseline, 1 week after
implantation of the DJBL, and
just prior to DJBL explantation.
b The area under the curve
calculations for PYY. c Plasma
CCK concentrations obtained
during the meal tolerance tests
and d shows the area under the
curve calculations for CCK.
e Plasma ghrelin levels during the
meal tolerance tests whereas
f displays the area under the curve
calculations for ghrelin. g The
fasting leptin plasma levels. An
asterisk (*) indicates p<0.05, two
asterisks indicate p<0.01. The
orange circles represent the
baseline time point, the dark blue
blocks represent the week 1 time
point, and the ss represent the
week 24 time point
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increasing satiety and reducing gut motility [30, 31]. Secretion
of the orexigenic hormone ghrelin, mainly by the stomach
fundus, is stimulated in the fasted state and plasma levels fall
shortly after food ingestion [32, 33]. Leptin is secreted by
adipocytes in proportion to whole body adipose tissue mass
and is a long term energy regulator.
In obese subjects, various aberrations in satiety regulation
have been described, with leptin resistance as the most report-
ed feature [34]. In addition, obesity is associated with altered
hormonal responses to food [11]. RYGB augments postpran-
dial PYY and GLP-1 levels and increases satiety [15–18]. In
line, the current study shows that the postprandial PYY re-
sponse was increased after implantation of the DJBL. Previ-
ously, we reported on increased postprandial GLP-1 levels in
DJBL treated patients [24]. Interestingly, subjects treated with
the DJBL also reported increased satiety and reduced caloric
intake. The underlying mechanism for the increased PYYand
GLP-1 levels might be related to the presence of undigested
nutrients in the distal gut, where PYY and GLP-1 secreting
cells are predominantly located. Both the RYBG and the
DJBL prevent uptake and digestion of nutrients in the proxi-
mal small intestine. As a result, undigested nutrients will be
present more distally in the small intestine [30, 31]. In accor-
dance to the ileal brake theory, intestinal feedback mecha-
nisms, such as PYY and GLP-1, are activated by undigested
nutrients in the distal gut, reducing food intake and increasing
satiety by delaying gut motility [35, 36].
To obtain insight into changes in additional hormones in-
volved in appetite control, postprandial levels of CCK, a hor-
mone with important digestive and satiety functions, were
determined. After implantation of the DJBL, the CCK re-
sponse to a meal decreased. We propose that the absence of
direct contact of food with the proximal small gut, where the
CCK producing I-cells are predominantly located, might ex-
plain the decreased CCK response after DJBL treatment. This
decrease in CCK levels could lead to a decrease in satiety.
However, in obese subject CCK resistance has been suggested
[37], putatively reducing the aforementioned effect.
Furthermore, DJBL implantation resulted in an enhanced
postprandial ghrelin response. After DJBL placement, fasting
ghrelin levels were increased but a more distinct postprandial
reduction in concentrations was present. Taking into account
the wide spectrum of physiological functions of ghrelin
[33, 38] and the controversial results obtained following other
bariatric procedures [20], these changes are not easily ex-
plained. However, the more pronounced decrease in postpran-
dial ghrelin levels after DJBL placement might be associated
with increased satiety following meal ingestion. Furthermore,
although the stomach is the principal site of ghrelin produc-
tion, up to one third of the circulating ghrelin is thought to
originate from the proximal small intestine [39]. The increased
(fasting) ghrelin levels might therefore be induced by the ex-
clusion of this part of the intestine from nutrients, thereby
locally mimicking starvation. Additionally, circulating ghrelin
levels have been reported to be inversely correlated with adi-
pose tissuemass [12, 13]. The subjects in the current study lost
a significant amount of weight; therefore, loss of adipose tis-
sue mass might be expected. In line, leptin levels decreased
along with BMI, presumably reflecting reduced adipose tissue
mass [18, 21].
Subjects included in the current study suffered from both
obesity and type 2 diabetes. In these subjects, with insulin
resistance, satiety control is probably even more disturbed
than in subjects with obesity alone since insulin is involved
in satiety control via signaling of long term energy stores [40].
Interestingly, increased insulin sensitivity has been reported
following both bariatric surgery [41] and DJBL placement
[22, 24, 42].
A limitation of our study is the uncontrolled nature of the
study. Patients were advised calorie restriction in combination
with DJBL treatment. Studies comparing the combination of
bariatric surgery with dietary regimens to dietary restriction
alone are scarce. Evens, et al., described an increase in the
postprandial PYYand GLP-1 levels after RYGB independent
of caloric restriction [43]. However, the effect of weight loss
due to caloric restriction, especially on the longer term, cannot
be excluded.
In conclusion, our data show that DJBL treatment induces
weight loss paralleled by changes in plasma concentrations of
hormones involved in appetite control. The improved hor-
monal profiles may attenuate weight regain after removal of
the DJBL or aid the effectiveness of other therapies to main-
tain weight loss.
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